2026-06-29T23:02:17Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/79932023-11-23T12:24:34Zcom_10259_4862com_10259_5086com_10259_2604col_10259_4863

Aydillo, Teresa Escalera, Alba Strohmeier, Shirin Aslam, Sadaf Sánchez Céspedes, Javier Ayllón Barasoain, Juan Roca Oporto, Cristina Pérez Romero, Pilar Montejo, Miguel Gavalda, Joan Muñoz, Patricia López Medrano, Francisco Carratala, Jordi Krammer, Florian García Sastre, Adolfo Cordero, Elisa 2023-11-10T13:45:57Z 2023-11-10T13:45:57Z 2020 2666-3791 http://hdl.handle.net/10259/7993 10.1016/J.XCRM.2020.100130 Hemagglutination-inhibitory antibodies are usually highly strain specific with little effect on infection with drifted or shifted strains. The significance of broadly cross-reactive non-HAI anti-influenza antibodies against conserved domains of virus glycoproteins, such as the hemagglutinin (HA) stalk, is of great interest. We characterize a cohort of 40 H1N1pmd09 influenza-infected patients and identify lower respiratory symptoms (LRSs) as a predictor for development of pneumonia. A binomial logistic regression of log10 pre-existing antibody values shows that the probability of LRS occurrence decreased with increased anti-HA full-length and stalk antibody ELISA titers. However, a multilevel logistic regression model adjusted by other potential serocorrelates demonstrates that only antibodies directed against the stalk of HA correlate with protection from lower respiratory infection, limiting disease progression. Our predictive model indicates that a threshold of protective immunity based on broadly cross-reactive HA stalk antibodies could be feasible. This work was supported by the Programa de Investigación sobre gripe A/H1N1, Instituto de Salud Carlos III, Ministerio. de Ciencia e Innovación (GR09/0041); the Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III, co-financed by the European Development Regional Fund “A way to Achieve Europe” ERDF; the Spanish Network for Research in Infectious Diseases (REIPI RD06/0008 to E.C.); NIAID grants P01AI097092 and U19AI135972; CRIP (Center for Research on Influenza Pathogenesis), an NIAID-funded Center of Excellence on Influenza Research and Surveillance (CEIRS; contract HHSN272201400008C); and SEM-CIVIC, an NIAID-funded Collaborative Influenza Vaccine Innovation Center (contract 75N93019C00051 to A.G.-S. and F.K.). application/pdf eng Cell Press Cell Reports Medicine. 2020, V. 1, n. 8, 100130 https://doi.org/10.1016/j.xcrm.2020.100130 Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess Influenza antibodies Correlates of protection Transplant patients Viral pneumonia Medicina Microbiología Enfermedades infecciosas Medicine Microbiology Communicable diseases Pre-existing Hemagglutinin Stalk Antibodies Correlate with Protection of Lower Respiratory Symptoms in Flu-Infected Transplant Patients info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Cell Reports Medicine 1 8 100130